Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 62 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc | RARE | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 39.80 | 08:52:50 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 39.80 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 3 | 62 | - | 31.52 - 54.56 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 08:44:50 | 1 | $ 39.17 | USD |
Ultragenyx Pharmaceutical Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 3.28B | 82.34M | - | 434.25M | -606.64M | -7.37 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Ultragenyx Pharmaceutical News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RARE Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 41.47 | 45.59 | 38.16 | 40.87 | 1,715,178 | -1.67 | -4.03% |
| 1 Month | 41.39 | 45.59 | 37.82 | 40.65 | 954,440 | -1.59 | -3.84% |
| 3 Months | 45.97 | 52.56 | 37.82 | 42.90 | 812,088 | -6.17 | -13.42% |
| 6 Months | 45.94 | 54.56 | 37.82 | 45.14 | 785,560 | -6.14 | -13.37% |
| 1 Year | 48.20 | 54.56 | 31.52 | 41.81 | 781,228 | -8.40 | -17.43% |
| 3 Years | 94.52 | 104.38 | 31.52 | 51.73 | 653,738 | -54.72 | -57.89% |
| 5 Years | 61.91 | 179.647 | 31.52 | 60.86 | 586,487 | -22.11 | -35.71% |
Ultragenyx Pharmaceutical Description
| Ultragenyx Pharmaceutical Inc is a US-based biopharmaceutical company. It identifies, acquires, develops, and commercialize novel products for the treatment of serious rare and ultra-rare diseases, with the focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. |
